Lucia Pantani

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.

Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.

Journal: Blood advances

Published: April 15, 2026

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

Journal: European journal of haematology

Published: December 16, 2025

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Journal: Clinical and experimental medicine

Published: August 26, 2025

Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.

Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.

Journal: Frontiers in oncology

Published: July 24, 2025

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal: Journal of cancer research and clinical oncology

Published: May 14, 2025

Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.

Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.

Journal: Mediterranean journal of hematology and infectious diseases

Published: March 13, 2025

Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.

Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.

Journal: Clinical and experimental medicine

Published: February 17, 2025

Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.

Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.

Journal: Haematologica

Published: February 16, 2025

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Journal: Journal of bone oncology

Published: December 21, 2024

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.

Journal: Cancers

Published: July 10, 2024

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.

Journal: Blood cancer journal

Published: July 01, 2024

Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.

Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.

Journal: Expert review of anticancer therapy

Published: May 27, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026